<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019419</url>
  </required_header>
  <id_info>
    <org_study_id>A2016-J000-001</org_study_id>
    <nct_id>NCT03019419</nct_id>
  </id_info>
  <brief_title>Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokyo Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and the efficacy of perampanel in patients with sporadic
      amyotrophic lateral sclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of peramanel for 48 weeks on progression of disease in subjects with
      ALS, as measured by ALS Functional Rating Scale-Revised (ALSFRS-R)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ALS Functional rating scale</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ALS Functional rating scale</measure>
    <time_frame>12, 24, 36, and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Test</measure>
    <time_frame>12, 24, 36, and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent-predicted forced vital capacity</measure>
    <time_frame>12, 24, 36, and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Perampanel 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily placebo for control for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>4mg/d or 8mg/d</description>
    <arm_group_label>Perampanel 4mg</arm_group_label>
    <arm_group_label>Perampanel 8mg</arm_group_label>
    <other_name>non-competitive AMAP antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Eligibility Criteria for Interim Registration]

          -  Patients who are able to submit written informed consent. If patients are duly capable
             of study consent but are unable to sign by themselves due to aggravation of disease
             condition, written informed consent can be obtained from a legally authorized
             representative who can sign on behalf of the patients after confirming the patients'
             agreement to study participation.

          -  Patients who are male or female aged 40 years to 78 years at the time of obtaining
             informed consent

          -  Patients who have clinically definite ALS, clinically probable ALS, or clinically
             probable-laboratory supported ALS as specified in the revised El Escorial Airlie House
             diagnostic criteria.

          -  The sum of the 3 respiratory items of the ALSFRS-R must total 12 points or more

          -  Patients within 2-year elapsed time period from disease onset at the time of obtaining
             informed consent

          -  Patients who can visit study site for out-patient treatment

        [Eligibility Criteria for Registration]

        Subjects who meet the following criteria in addition to the inclusion criteria for the
        interim registration

          -  The progression on score of ALSFRS-R during 12 weeks of observation period must be
             between -2 and -5

          -  Patients who has not initiated newly introduced riluzole therapy after starting the
             observation period. Or those who has not received dose escalation or resumed
             administration of riluzole therapy after previous down titration or discontinuation

          -  Patients who has not initiated newly introduced edaravone therapy after starting the
             observation period

          -  Patients who are judged to be eligible for continuation of the study by the
             investigators

        [Exclusion Criteria]

          -  Patients who underwent tracheostomy.

          -  Patients who experienced non-invasive positive pressure ventilation.

          -  Patients whose percent-predicted forced vital capacity (%FVC) is â‰¤80%.

          -  Patients with progressive bulbar palsy type.

          -  Patients with cognitive impairment, severe disease in the renal, cardiovascular, or
             hematological system.

          -  Patients with hepatic disease.

          -  Patients with malignant tumor.

          -  Pregnant women or women with a possibility of becoming pregnant.

          -  Patients who participated in another clinical study within 12 weeks before starting
             the observation period.

          -  Patients who has initiated perampanel therapy in the past or at present.

          -  Patients who are judged to be ineligible for study entry by the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomohiro Haga</last_name>
    <role>Study Director</role>
    <affiliation>The University of Tokyo Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hitoshi Aizawa, MD,PhD</last_name>
    <phone>+81-3-3342-6111</phone>
    <email>haizawa@tokyo-med.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tomohiro Haga</last_name>
    <phone>+81-3-5800-9762</phone>
    <email>tomohirohaga-tky@umin.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kitasato University East Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makiko Nagai, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto Saishunso National Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidetsugu Ueyama, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahisa Katsuno, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koji Abe, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ichiro Yabe, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hitoshi Warita, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makoto Urushitani, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haruhisa Kato, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Ishiura, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Neurological Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akihiro Kawata, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Tamaoka, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takashi Kanda, MD,PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>April 29, 2018</last_update_submitted>
  <last_update_submitted_qc>April 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sporadic ALS</keyword>
  <keyword>perampanel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

